长药控股年报被出具非标审计意见；康泰生物2024年归母净利同比下滑超七成

Group 1 - Changyao Holdings reported a negative net asset for the end of 2024 and has faced three consecutive years of negative net profit, leading to a non-standard audit opinion and potential delisting risk [1] - Hengrui Medicine's second-generation PARP inhibitor HRS-1167 has received clinical trial approval for treating metastatic prostate cancer, indicating potential for broader application in oncology [2] - Baike Biotech's revenue for 2024 decreased by 32.64% to 1.229 billion yuan, with a net profit drop of 53.67% primarily due to reduced sales of its shingles vaccine [3] Group 2 - Kangtai Biological's revenue fell by 23.75% in 2024, with a net profit decline of 76.60%, attributed to market competition and inventory reduction strategies [4] - Changchun High-tech reported a 7.55% decrease in revenue to 13.466 billion yuan for 2024, with a net profit decline of 43.01%, facing challenges from centralized procurement policies and intensified industry competition [5]